Biosimilar Prescribing Decisions May Depend Upon Disease State
Executive Summary
Express Scripts’ Eichholz says clinicians may be less inclined to use a biosimilar in ‘life or death’ oncology indications compared to inflammatory diseases.
You may also be interested in...
US Market For Therapeutic Cancer Biosimilars Will Be Tested By Mvasi, Kanjinti Launches
Amgen and Allergan’s launch of the first biosimilars to Roche/Genentech’s Avastin and Herceptin may not face the same commercial dynamics that have stymied biosimilars in other therapeutic areas, but uptake could depend upon oncologists’ comfort level in prescribing the follow-on agents.
Will Epoetin Biosimilar Serve As Non-Medical Switching Case Study?
Analysts expect potential broad uptake of biosimilars in chronic kidney disease treated at dialysis centers, which could lead to patients being switched off Amgen's Epogen.
Will Epoetin Biosimilar Serve As Non-Medical Switching Case Study?
Analysts expect potential broad uptake of biosimilars in chronic kidney disease treated at dialysis centers, which could lead to patients being switched off Amgen's Epogen.